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Purpose/Objective: To determine risk factors for local-regional 
recurrences (LRR) after mastectomy and adjuvant radiotherapy for 
breast cancer (BC) patients 
Materials and Methods: From January 2000 till December 2005, 749 
BC patients were treated in a single institution with mastectomy, 
axillary dissection and postmastectomy radiotherapy (PMRT). Neo-
adjuvant and/or adjuvant chemotherapy was given in 57.8% of the 
patients and 77.2% also received endocrine therapy. Indications for 
PMRT are pN+, pT3, pT4 and positive surgical margins. 15.4% (115) of 
the patients received radiotherapy of the chest wall alone and 67.6% 
(506) of the patients underwent irradiation of the chest wall with 
regional nodal irradiation (RNI). RNI involved radiotherapy to the 
internal mammary and medial supraclavicular nodes (IM-MS) in 67.4% 
and to the IM-MS and axilla in 32.6%. In 17.1% (128) of the patients 
with a pT1-2 tumour, only the IM-MS are irradiated (without chest wall 
irradiation) because of a medially or centrally located tumour. All 
clinical and pathological data were reviewed retrospectively. The 
association between categorical variables and the risk to relapse is 
tested by means of the log-rank test (univariate analysis). 
Results: At a median follow-up of 9 years, 26 of 749 patients (3.5%) 
developed LRR. Five- and 10-years local-regional control rates were 
97.6% and 96.0%. Predictive factors to develop LRR are grade 3 
tumours (p=0.009), pT4 (p<0.001), pN3 (p=0.03), estrogen receptor 
(ER) negative BC (p<0.001), progesterone receptor (PR) negative BC 
(p=0.006), Her-2 receptor positive BC (p=0.03) and triple negative BC 
(p=0.02). There was no association between LRR and tumour type 
(p=0.3), extensive intraductal component (p=0.7) and positive surgical 
margins (p=0.06). We also found no correlation between age and LRR 
(p=0.2) (Cox proportional hazards model). By the time of the congress 
we will be able to present the multivariate analysis as well. 
Conclusions: In breast cancer patients treated with mastectomy and 
adjuvant radiotherapy with or without systemic treatment the LRR at 
our institution are very low at 10 years. Notwithstanding few LRR, 
grade 3 tumours, pT4, pN3, ER negative, PR negative, Her-2 positive 
and triple negative BC are clear risk factors to develop LRR. 
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Purpose/Objective: Post mastectomy radiotherapy (PMRT) reduces 
loco-regional recurrence (LRR) and has been associated with survival 
benefit. International consensus recommends PMRT for patients with 
tumour size ≥5cm (T3), tumour invasion of the skin, pectoral muscle 
or chest wall (T4) and patients with ≥ 4 positive lymph nodes (LN). 
The role of PMRT for patients with 1-3 positive LN and LN negative 
patients is contentious. Apart from LN status, other prognostic factors 
for LRR include tumour grade, tumour size and lymphovascular 
invasion (LVI). It is unclear how these prognostic factors should be 
used to select patients for PMRT. In 1999, an index was designed 
based on these prognostic factors at the Cambridge Breast Unit (CBU) 
for patient selection. This study reports a 10 year experience using 
the C-PMRT index. 
Materials and Methods: The C-PMRT index was constructed with 
scores (1-3) allocated in each of four categories including the number 
of positive LN/LVI, tumour size, margin status and tumour grade 
(Table 1). Patients with tumour T3/T4 tumour or with ≥ 4 positive LN 
were categorised as high (H) risk. Other patients with an aggregate 
score of ≥ 3 on C-PMRT were categorised as Intermediate (I) risk and 
<3 as low (L) risk. PMRT was recommended for H and I risk patients. 
The LRR, distant metastasis and overall survival (OS) data was 
collected from patient's records. The length of follow up or time to an 
event was measured from the day of mastectomy. 
 
Table 1: Cambridge Post-Mastectomy Radiotherapy (C-PMRT) Index 
Score 3 2 1 
Number of positive 
lymph nodes or LVI 
≥ 4 1-3 LVI 
Invasive tumour size >50mm (T3)  
or T4 
30-
50mm 
20-29 
mm 
Excision margins Deep margin < 1mm or 
pectoral muscle invasion 
  
Tumour grade   Grade 
3 
 
LVI: Lymphovascular invasion. 
T4: Tumour of any size with direct extension to the chest wall and/or 
to the skin (ulceration or skin nodules) 
 
Results: From 1999-2009, 898 invasive breast cancers in 883 patients 
were treated by mastectomy at the CBU (H: 323, I: 231 and L: 344). 
All patients underwent axillary sampling ± axillary clearance. Median 
age was 60 years (range 23-96) and at a median follow up of 5.2 years, 
4.7% (42/898) developed LRR. The 5 yr actuarial LRR rates were 6%, 
2% and 3% for the H, I and L risk groups respectively (Figure 1). Only 
1.2% (11/898) developed isolated LRR (I risk group, n=0; H risk, n=3; L 
risk, n=8). The 5 yr actuarial OS survival rates were 67%, 77% and 90% 
for H, I and L risk groups respectively. 
 
 
Conclusions: Based on published literature, one would have expected 
a higher LRR rate in the I risk group without adjuvant RT. We 
hypothesise that the I risk group LRR rates have been reduced to that 
of the L risk group by the addition of RT. Apart from LN status, other 
prognostic factors should also be considered in selecting patients for 
PMRT (similar to selecting patients for systemic chemotherapy-
adjuvant online). This pragmatic tool requires further validation from 
randomised trial data. 
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Purpose/Objective: Ionizing radiation exposure can induce immediate 
cell membrane permeabilization, which inflicts loss of cell ionic 
equilibrium, depletion of adenosine triphosphate (ATP) and formation 
of reactive oxidative species (ROS). This manifests through 
morphological changes, including cellular swelling, shrinkage, 
blebbing, lysis and extracellular edema, depending on severity of 
permeabilization. In this study we mimic radiation induced brain 
tissue permeabilization, through the application of local static 
electric fields (electroporation) in vivo. The purpose of the study is to 
evaluate diffusion weighted MRI (DW-MRI) as a non-invasive technique 
